Efficacy of Tixagevimab and Cilgavimab Against SARS-CoV-2 Infections in Patients with Inborn Errors of Immunity.
Publication
, Journal Article
Johnson, S; McDonnell, JC; Fernandez, JM
Published in: J Clin Immunol
July 2023
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
J Clin Immunol
DOI
EISSN
1573-2592
Publication Date
July 2023
Volume
43
Issue
5
Start / End Page
865 / 868
Location
Netherlands
Related Subject Headings
- SARS-CoV-2
- Immunology
- Humans
- COVID-19
- Antibodies, Monoclonal
- 3204 Immunology
- 1107 Immunology
Citation
APA
Chicago
ICMJE
MLA
NLM
Johnson, S., McDonnell, J. C., & Fernandez, J. M. (2023). Efficacy of Tixagevimab and Cilgavimab Against SARS-CoV-2 Infections in Patients with Inborn Errors of Immunity. J Clin Immunol, 43(5), 865–868. https://doi.org/10.1007/s10875-023-01457-z
Johnson, Sarah, John C. McDonnell, and James M. Fernandez. “Efficacy of Tixagevimab and Cilgavimab Against SARS-CoV-2 Infections in Patients with Inborn Errors of Immunity.” J Clin Immunol 43, no. 5 (July 2023): 865–68. https://doi.org/10.1007/s10875-023-01457-z.
Johnson S, McDonnell JC, Fernandez JM. Efficacy of Tixagevimab and Cilgavimab Against SARS-CoV-2 Infections in Patients with Inborn Errors of Immunity. J Clin Immunol. 2023 Jul;43(5):865–8.
Johnson, Sarah, et al. “Efficacy of Tixagevimab and Cilgavimab Against SARS-CoV-2 Infections in Patients with Inborn Errors of Immunity.” J Clin Immunol, vol. 43, no. 5, July 2023, pp. 865–68. Pubmed, doi:10.1007/s10875-023-01457-z.
Johnson S, McDonnell JC, Fernandez JM. Efficacy of Tixagevimab and Cilgavimab Against SARS-CoV-2 Infections in Patients with Inborn Errors of Immunity. J Clin Immunol. 2023 Jul;43(5):865–868.
Published In
J Clin Immunol
DOI
EISSN
1573-2592
Publication Date
July 2023
Volume
43
Issue
5
Start / End Page
865 / 868
Location
Netherlands
Related Subject Headings
- SARS-CoV-2
- Immunology
- Humans
- COVID-19
- Antibodies, Monoclonal
- 3204 Immunology
- 1107 Immunology